The Relationship of Vitamin D Serum Levels with The Lowering of The Left Ventricular Systolic Function in Women with Locally Advanced Breast Cancer Undergoing Doxorubicin Chemotherapy

Abstract

Rheno Arditya, Hantoro Ishardyanto, Achmad Lefi, Edwin Danardono4

Chemotherapy with doxorubicin in breast cancer patients can cause cardiotoxicity and increase mortality by up to 50%. Vitamin D can cause indirect effects on decreasing heart function. This study examined the relationship of serum blood vitamin D levels with decreased left ventricular systolic function in women with locally advanced breast cancer (LBAC) undergoing doxorubicin chemotherapy. This was an analytical observational study with cross-sectional design. Data collection for vitamin D and echocardiography was performed on patients undergoing chemotherapy for one year. The data were then tested using the contingency coefficient test and regression test. This study found vitamin D deficiency in 17 persons (56.7%). On echocardiography examination, the mean left ventricular ejection fraction (LVEF) was obtained before administering neoadjuvant chemotherapy by 65.0±3, and the average LVEF after administration of neoadjuvant chemotherapy was 61.80±6.283. A total of 18 patients (60%) experienced decreased left ventricular systolic function. There was a significant relationship between vitamin D levels and decreased left ventricular systolic function (p = 0.007). There was a statistically significant relationship between vitamin D levels and decreased systolic function in women with LBAC undergoing neoadjuvant chemotherapy. The higher serum vitamin D level, the lower the decrease in left ventricular systolic function after undergoing Doxorubicin chemotherapy